Dr. Eric G. Auerbach, M.D.
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Medical school
- University of Miami, Lm Miller School of Medicine (1995)
- Years since graduation
- 31
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,024
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1995Medical school: University of Miami, Lm Miller School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
OK license 23429 -
Specialist
OK license 23429
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hillcrest Medical Center Tulsa, OK
- Hillcrest Hospital South Tulsa, OK
- Bailey Medical Center, LLC Owasso, OK
- Hillcrest Hospital Cushing Cushing, OK
- Cleveland Area Hospital Cleveland, OK
Medical groups
- Ahs Oklahoma Heart LLC (132 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,024
- Services billed
- 1,824
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 286 | 286 |
| Established patient office or other outpatient visit, 30-39 minutes | 279 | 223 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 271 | 271 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 223 | 222 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 126 | 125 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 115 | 115 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 101 | 56 |
| Ct scan of blood vessels and grafts of heart with contrast | 76 | 74 |
| Established patient office or other outpatient visit, 20-29 minutes | 51 | 50 |
| Analysis of data from ct study of heart blood vessels to assess severity of heart artery disease, anatomical data review | 49 | 47 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ezetimibe Other prescribers in Tulsa, OK | 263 |
| Rosuvastatin Calcium Other prescribers in Tulsa, OK | 241 |
| Carvedilol Other prescribers in Tulsa, OK | 239 |
| Metoprolol Succinate Other prescribers in Tulsa, OK | 219 |
| Atorvastatin Calcium Other prescribers in Tulsa, OK | 199 |
| Eliquis (apixaban) Other prescribers in Tulsa, OK | 180 |
| Lisinopril Other prescribers in Tulsa, OK | 131 |
| Clopidogrel (clopidogrel bisulfate) Other prescribers in Tulsa, OK | 110 |
| Valsartan-Hydrochlorothiazide (valsartan/hydrochlorothiazide) Other prescribers in Tulsa, OK | 109 |
| Amlodipine Besylate Other prescribers in Tulsa, OK | 108 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 9 payments worth $254 in total to this clinician.
| Abiomed | $174 |
|---|---|
| Amgen Inc. | $33.25 |
| E.r. Squibb & Sons, L.l.c. | $28.80 |
| Boston Scientific Corporation | $18.23 |
| Food and Beverage | $254 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $41,350 in research payments for these studies, mostly to the institutions running them.
- Study name not reported
Ionis Pharmaceuticals, Inc. - Study name not reported
Ionis Pharmaceuticals, Inc. - A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.